Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apellis Pharmaceuticals (APLS) Net Margin (2020 - 2025)

Historic Net Margin for Apellis Pharmaceuticals (APLS) over the last 6 years, with Q3 2025 value amounting to 47.04%.

  • Apellis Pharmaceuticals' Net Margin rose 762300.0% to 47.04% in Q3 2025 from the same period last year, while for Sep 2025 it was 4.43%, marking a year-over-year increase of 394000.0%. This contributed to the annual value of 25.32% for FY2024, which is 1079700.0% up from last year.
  • Latest data reveals that Apellis Pharmaceuticals reported Net Margin of 47.04% as of Q3 2025, which was up 762300.0% from 23.63% recorded in Q2 2025.
  • Over the past 5 years, Apellis Pharmaceuticals' Net Margin peaked at 47.04% during Q3 2025, and registered a low of 35183.15% during Q2 2021.
  • For the 5-year period, Apellis Pharmaceuticals' Net Margin averaged around 2403.3%, with its median value being 127.77% (2023).
  • Examining YoY changes over the last 5 years, Apellis Pharmaceuticals' Net Margin showed a top increase of 342275200bps in 2022 and a maximum decrease of -4870600bps in 2022.
  • Over the past 5 years, Apellis Pharmaceuticals' Net Margin (Quarter) stood at 245.37% in 2021, then crashed by -199bps to 732.43% in 2022, then skyrocketed by 92bps to 60.51% in 2023, then soared by 72bps to 17.09% in 2024, then surged by 375bps to 47.04% in 2025.
  • Its last three reported values are 47.04% in Q3 2025, 23.63% for Q2 2025, and 55.29% during Q1 2025.